DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
299	嚢胞性線維症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03119649 (ClinicalTrials.gov)	March 18, 2017	11/4/2017	A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis	A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Multiple Doses of GLPG2222 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation	Cystic Fibrosis	Drug: GLPG2222 50 mg;Drug: GLPG2222 100 mg;Drug: Placebo;Drug: GLPG2222 200 mg;Drug: GLPG2222 400 mg	Galapagos NV	NULL	Completed	18 Years	99 Years	All	59	Phase 2	United States;Belgium;Netherlands;Serbia;Spain;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03119649
(ClinicalTrials.gov)

March 18, 2017

11/4/2017

A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Multiple Doses of GLPG2222 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation

Cystic Fibrosis

Drug: GLPG2222 50 mg;Drug: GLPG2222 100 mg;Drug: Placebo;Drug: GLPG2222 200 mg;Drug: GLPG2222 400 mg

Galapagos NV

NULL

Completed

18 Years

99 Years

All

Phase 2

United States;Belgium;Netherlands;Serbia;Spain;United Kingdom